Slopnick Emily A, Bagby Christina, Mahran Amr, Nagel Christa, Garcia Jorge, El-Nashar Sherif, Hijaz Adonis K
Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH.
Urology. 2022 Jul;165:36-43. doi: 10.1016/j.urology.2022.02.004. Epub 2022 Feb 19.
To present a recent clinical case of Skene's gland carcinoma and review all published literature of Skene's gland malignancy with associated treatment and outcomes.
We review a new case of metastatic Skene's gland adenocarcinoma. We then performed a systematic search of PubMed and Ovid-Medline through December 2021 and retrieved English language articles for review. Peer-reviewed articles were deemed eligible if they included patients with Skene's gland malignancy. Reports were reviewed for pathologic accuracy, patient characteristics, clinical presentation, tumor pathology, treatment and outcome.
We reviewed 211 articles and included 15 cases from 1974 to 2022. The median patient age was 71 years (range 46-88). The most common presentation was an asymptomatic periurethral or urethral lesion in five cases (33.3%), followed by hematuria or vaginal bleeding in three patients (20.0%). In eight cases, a prostate-specific antigen was measured and found to be elevated, range 0.8-60.8 ng/mL. Treatment approaches varied and included local excision in eight cases, radical surgical resection in two cases, radiation therapy in two cases, and adjunctive androgen deprivation therapy in one case. Pathology was consistent with adenocarcinoma resembling prostate in all cases. In all cases tested, prostate-specific antigen normalized after definitive therapy of any type. Median follow up was 11.5 months, and there were no cases of recurrence or mortality secondary to Skene's gland adenocarcinoma.
There are 15 published cases of a Skene's gland malignancy, all adenocarcinoma resembling prostate. Local excision is most often utilized for treatment, with androgen deprivation therapy emerging as a new treatment consideration.
介绍一例近期的斯基恩氏腺腺癌临床病例，并回顾所有已发表的关于斯基恩氏腺恶性肿瘤的文献，包括相关治疗方法及结果。
我们回顾了一例转移性斯基恩氏腺腺癌新病例。然后在2021年12月前对PubMed和Ovid-Medline进行了系统检索，检索英文文章以供综述。如果同行评审文章纳入了斯基恩氏腺恶性肿瘤患者，则被视为符合条件。对报告进行病理准确性、患者特征、临床表现、肿瘤病理、治疗及结果方面的审查。
我们回顾了211篇文章，纳入了1974年至2022年的15例病例。患者中位年龄为71岁（范围46 - 88岁）。最常见的表现是5例（33.3%）出现无症状的尿道周围或尿道病变，其次是3例（20.0%）出现血尿或阴道出血。8例患者检测了前列腺特异性抗原，发现其升高，范围为0.8 - 60.8 ng/mL。治疗方法多样，包括8例局部切除、2例根治性手术切除、2例放射治疗和1例辅助雄激素剥夺治疗。所有病例的病理均与前列腺样腺癌一致。在所有检测病例中，任何类型的确定性治疗后前列腺特异性抗原均恢复正常。中位随访时间为11.5个月，没有因斯基恩氏腺腺癌导致复发或死亡的病例。
已发表了15例斯基恩氏腺恶性肿瘤病例，均为前列腺样腺癌。局部切除是最常用的治疗方法，雄激素剥夺治疗成为一种新的治疗考虑。
